1262419-96-4 Usage
Description
Methyl 2-fluoro-3-formylbenzoate, a chemical compound with the molecular formula C9H7FO3, belongs to the class of organic compounds known as benzaldehydes. It is a yellow liquid with a slightly fruity odor and is primarily used as an intermediate in the synthesis of other compounds in the pharmaceutical industry. Additionally, it is utilized in the production of fragrances and flavoring agents. Although it is considered to have low toxicity, proper precautions should be taken when handling it.
Uses
Used in Pharmaceutical Industry:
Methyl 2-fluoro-3-formylbenzoate is used as an intermediate in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and medications.
Used in Fragrance Industry:
Methyl 2-fluoro-3-formylbenzoate is used as a component in the production of fragrances, providing a slightly fruity scent to various products.
Used in Flavoring Industry:
Methyl 2-fluoro-3-formylbenzoate is also utilized in the creation of flavoring agents, enhancing the taste and aroma of food and beverages.
Check Digit Verification of cas no
The CAS Registry Mumber 1262419-96-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,2,4,1 and 9 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1262419-96:
(9*1)+(8*2)+(7*6)+(6*2)+(5*4)+(4*1)+(3*9)+(2*9)+(1*6)=154
154 % 10 = 4
So 1262419-96-4 is a valid CAS Registry Number.
1262419-96-4Relevant articles and documents
The discovery of diazepinone-based 5-HT3 receptor partial agonists
Manning, David D.,Guo, Cheng,Zhang, Zhenjun,Ryan, Kristen N.,Naginskaya, Jennifer,Choo, Sok Hui,Masih, Liaqat,Earley, William G.,Wierschke, Jonathan D.,Newman, Amy S.,Brady, Catherine A.,Barnes, Nicholas M.,Guzzo, Peter R.
, p. 2578 - 2581 (2014/05/20)
Serotonin type 3 (5-HT3) receptor partial agonists have been targeted as potential new drugs for the symptomatic relief of irritable bowel syndrome (IBS). Multiple diazepinone-based compounds have been discovered, which exhibit nanomolar bindin
